mhurhangee/patent-ind-claim-en huggingface dataset:
A bogie of a railway vehicle capable of being moved from a rest configuration to an active configuration in which the bogie supports at least one vertical load, the bogie comprising: - a chassis , - at least one pair of wheels , - for each pair of wheels , a shaft connecting the two wheels of said pair of wheels , each shaft extending along an axle axis (A-A'), - for each wheel , a wheel hub attached to the wheel and the associated shaft , said shaft being inserted into the hub , each hub extending along a hub axis (B-B'), - for each wheel , an axle box fixed to the chassis and receiving the associated hub , each hub being rotatable relative to the associated axle box , characterised in that , for each hub , the hub axis (B-B') forms a non-zero camber angle (a) with the axle axis (A-A') of the associated shaft when the bogie is in the rest configuration. - a chassis , - at least one pair of wheels , - for each pair of wheels , a shaft connecting the two wheels of said pair of wheels , each shaft extending along an axle axis (A-A'), - for each wheel , a wheel hub attached to the wheel and the associated shaft , said shaft being inserted into the hub , each hub extending along a hub axis (B-B'), - for each wheel , an axle box fixed to the chassis and receiving the associated hub , each hub being rotatable relative to the associated axle box ,
A network hub device (31-37) used in an in-vehicle network system, comprising: a trunk side communication port configured to couple to a trunk network through which a digital control signal of a predetermined first protocol is transmitted, said trunk network being coupled to a central processing unit provided in the in-vehicle network system; a plurality of device side communication ports (42 - 49) serving as communication ports each performing input/output of a signal to/from an in-vehicle device and including a first digital port configured to perform input/output of the digital control signal and a first analog port (45-48) configured to perform input/output of an analog control signal; a signal conversion section provided between the trunk side communication port and the first analog port (45-48) and configured to perform signal conversion between the digital control signal of the first protocol and the analog control signal input/output by the first analog port (45-48); characterized in that the network hub device (31-37) further comprises a second signal conversion section provided between the first digital port and a predetermined in-vehicle device and configured to perform signal conversion between the digital control signal input/output by the first digital port and the analog control signal input/output by the predetermined in-vehicle device , wherein the second signal conversion section is provided separately to the signal conversion section and is formed with a circuit substrate of the predetermined in-vehicle device as one unit. a trunk side communication port configured to couple to a trunk network through which a digital control signal of a predetermined first protocol is transmitted, said trunk network being coupled to a central processing unit provided in the in-vehicle network system; a plurality of device side communication ports (42 - 49) serving as communication ports each performing input/output of a signal to/from an in-vehicle device and including a first digital port configured to perform input/output of the digital control signal and a first analog port (45-48) configured to perform input/output of an analog control signal; a signal conversion section provided between the trunk side communication port and the first analog port (45-48) and configured to perform signal conversion between the digital control signal of the first protocol and the analog control signal input/output by the first analog port (45-48); characterized in that the network hub device (31-37) further comprises a second signal conversion section provided between the first digital port and a predetermined in-vehicle device and configured to perform signal conversion between the digital control signal input/output by the first digital port and the analog control signal input/output by the predetermined in-vehicle device , wherein the second signal conversion section is provided separately to the signal conversion section and is formed with a circuit substrate of the predetermined in-vehicle device as one unit.
An antimicrobial nanoparticle having inherent antimicrobial activity comprising: an antimicrobial adhesive protein comprising an antibiotic peptide linked to a mussel adhesive protein derivative of which a tyrosine residue in the mussel adhesive protein is modified to a catechol derivative; and a metal capable of coordinating with the mussel adhesive protein derivative, wherein the antimicrobial nanoparticle has an antimicrobial effect at a pH of from 0.1 to 6.5, wherein the mussel adhesive protein is a protein selected from the group consisting of Mytilus edulis foot protein (Mefp)-1, Mefp-2, Mefp-3, Mefp-4, Mefp-5, Mytilus galloprovincialis foot protein (Mgfp)-1, Mgfp-2, Mgfp-3, Mgfp-4, Mgfp-5, Mytilus coruscus foot protein (Mcfp)-1,Mcfp-2, Mcfp-3, Mcfp-4, Mcfp-5, foot protein (fp)-1, fp-2, fp-3, fp-4, fp-5 and fp-6, or a fusion protein to which the at least one protein selected from the group is linked, and wherein the catechol derivative is one selected from the group consisting of 3,4-dihydroxyphenylalanine (DOPA), DOPA o-quinone, dopamine, norepinephrine, epinephrine, and epigallocatechin gallate. an antimicrobial adhesive protein comprising an antibiotic peptide linked to a mussel adhesive protein derivative of which a tyrosine residue in the mussel adhesive protein is modified to a catechol derivative; and a metal capable of coordinating with the mussel adhesive protein derivative, wherein the antimicrobial nanoparticle has an antimicrobial effect at a pH of from 0.1 to 6.5, wherein the mussel adhesive protein is a protein selected from the group consisting of Mytilus edulis foot protein (Mefp)-1, Mefp-2, Mefp-3, Mefp-4, Mefp-5, Mytilus galloprovincialis foot protein (Mgfp)-1, Mgfp-2, Mgfp-3, Mgfp-4, Mgfp-5, Mytilus coruscus foot protein (Mcfp)-1,Mcfp-2, Mcfp-3, Mcfp-4, Mcfp-5, foot protein (fp)-1, fp-2, fp-3, fp-4, fp-5 and fp-6, or a fusion protein to which the at least one protein selected from the group is linked, and wherein the catechol derivative is one selected from the group consisting of 3,4-dihydroxyphenylalanine (DOPA), DOPA o-quinone, dopamine, norepinephrine, epinephrine, and epigallocatechin gallate.
A method for determining a position of a user equipment, UE, performed by the UE, the method comprising: receiving from a serving gNB assistance data for a plurality of gNBs, which includes the serving gNB, wherein the assistance data comprises the location of each gNB of the plurality of gNBs; transmitting to the plurality of gNBs uplink reference signals; receiving from the serving gNB uplink reference signal measurements measured by each of the plurality of gNBs, wherein the received uplink reference signal measurements are time-of-arrival, TOA, measurements; determining the position of the UE based on the uplink reference signal measurements measured by each of the plurality of gNBs and the assistance data for the plurality of the gNBs. receiving from a serving gNB assistance data for a plurality of gNBs, which includes the serving gNB, wherein the assistance data comprises the location of each gNB of the plurality of gNBs; transmitting to the plurality of gNBs uplink reference signals; receiving from the serving gNB uplink reference signal measurements measured by each of the plurality of gNBs, wherein the received uplink reference signal measurements are time-of-arrival, TOA, measurements; determining the position of the UE based on the uplink reference signal measurements measured by each of the plurality of gNBs and the assistance data for the plurality of the gNBs.
Security structure comprising: - at least one first fluorescent composition , - at least one second phosphorescent composition , the first and second compositions being able to be excited simultaneously by a predefined illuminant from one and the same first face of the structure, the security structure being in the form of a security thread, a security film or a patch, and the first fluorescent composition being superposed, at least partially, on the second phosphorescent composition, and/or the first and second compositions being applied in register on the security structure, a support of the security structure incorporating at least one barrier element to UV radiation and/or at least one barrier layer to UV radiation being applied on at least one of the fluorescent and phosphorescent compositions. - at least one first fluorescent composition , - at least one second phosphorescent composition , the first and second compositions being able to be excited simultaneously by a predefined illuminant from one and the same first face of the structure,
A composition for use in a method of (i) treating cancer in a human; (ii) augmenting vaccination in a human; (iii) increasing immune responses to cancer in a human; or (iv) enhancing immune system reconstitution following bone marrow or stem cell transplantation in a human, wherein the composition comprises: a pre-coupled polypeptide complex comprising an IL-15 polypeptide, and a soluble form of an IL-15Ra polypeptide, and wherein the complex is formed prior to administration.
A SiOC composite material in microparticulate form, wherein the microparticles comprise an amorphous silicon oxycarbide network of formula SiOC, also referred to as "SiOC matrix", with Si ranging from 20 wt% to 60 wt%, O from 20 wt% to 40 wt% and C from 10 wt% to 50 wt%, based on the total weight of the SiOC matrix, wherein amorphous or crystallized silicon particles are embedded within said SiOC matrix and wherein the microparticles are of core/coating structure with a core formed of said amorphous SiOC matrix and coated with at least one amorphous carbon layer, said microparticles having an average particle size ranging from 1 μm to 100 μm, said silicon particles being present in the SiOC matrix in a weight ratio SiOC matrix/Si particles ranging from 2 to 20.
A personalized neoplasia vaccine for use in treating a subject diagnosed as having a neoplasia, the personalized vaccine being obtained by: identifying a plurality of mutations in a biological sample of the neoplasia from the subject, wherein the identifying comprises sequencing the genome, transcriptome, or proteome of the neoplasia; analyzing the plurality of mutations to identify one or more neo-antigenic mutations predicted to encode expressed neo-antigenic peptides, the neo-antigenic mutations selected from the group consisting of missense mutations, neoORF mutations, and any combination thereof; allowing a synthetic High Density Lipoprotein (sHDL) nanoparticle comprising one or more thiol-reactive phospholipids, and at least one HDL apolipoprotein or apolipoprotein mimetic to complex with one or more neo-antigenic peptides specific for the analyzed and identified neo-antigenic mutations predicted to encode neo-antigenic peptides, wherein the one or more neo-antigenic peptides range from about 5 to about 50 amino acids in length, wherein the neo-antigenic peptide is complexed through a thiol-mediated interaction, to provide the personalized neoplasia vaccine, wherein the HDL apolipoprotein mimetic is an ApoA-I mimetic described by any of SEQ ID NOs: 1-235, 237-239, 241-254, 256-334, or 336. identifying a plurality of mutations in a biological sample of the neoplasia from the subject, wherein the identifying comprises sequencing the genome, transcriptome, or proteome of the neoplasia; analyzing the plurality of mutations to identify one or more neo-antigenic mutations predicted to encode expressed neo-antigenic peptides, the neo-antigenic mutations selected from the group consisting of missense mutations, neoORF mutations, and any combination thereof; allowing a synthetic High Density Lipoprotein (sHDL) nanoparticle comprising one or more thiol-reactive phospholipids, and at least one HDL apolipoprotein or apolipoprotein mimetic to complex with one or more neo-antigenic peptides specific for the analyzed and identified neo-antigenic mutations predicted to encode neo-antigenic peptides, wherein the one or more neo-antigenic peptides range from about 5 to about 50 amino acids in length, wherein the neo-antigenic peptide is complexed through a thiol-mediated interaction, to provide the personalized neoplasia vaccine, wherein the HDL apolipoprotein mimetic is an ApoA-I mimetic described by any of SEQ ID NOs: 1-235, 237-239, 241-254, 256-334, or 336.
A production method for an electrode for a power storage device, comprising: A slurry creation process for creating a liquid slurry or gel slurry which contains short fibers of aluminum or copper, adsorbent material powder on which electrolyte ions are adsorbed during charging or active material powder which chemically reacts during charging or discharging, and a binder; A formation process for forming the slurry into a predetermined shape; and A drying process for drying the slurry that was formed into the predetermined shape so as to form an electrode in which the short fibers of aluminum or copper functions as a current collector; wherein said current collector is a non-woven current collector formed by the short fibers of aluminum or copper; wherein said non-woven fabric current collector has at least one portion at which two of the short fibers of the aluminum or copper are in contact with each other in an intersection manner such that the two aluminum or copper fibers bite each other at the portion of the intersection. A slurry creation process for creating a liquid slurry or gel slurry which contains short fibers of aluminum or copper, adsorbent material powder on which electrolyte ions are adsorbed during charging or active material powder which chemically reacts during charging or discharging, and a binder; A formation process for forming the slurry into a predetermined shape; and A drying process for drying the slurry that was formed into the predetermined shape so as to form an electrode in which the short fibers of aluminum or copper functions as a current collector; wherein said current collector is a non-woven current collector formed by the short fibers of aluminum or copper; wherein said non-woven fabric current collector has at least one portion at which two of the short fibers of the aluminum or copper are in contact with each other in an intersection manner such that the two aluminum or copper fibers bite each other at the portion of the intersection.
Use of a solid fraction sensor to evaluate a solid fraction of a target pharmaceutical sample , wherein the solid fraction sensor has a first conductor element , a second conductor element , an operation space and an energy source arranged to generate an electric field in the operation space by means of the first conductor element and the second conductor element , comprising positioning the target pharmaceutical sample in the operation space of the solid fraction sensor , determining a capacitance between the first and second conductor elements with the target pharmaceutical sample located in the operation space , and converting the determined capacitance together with information about a composition of a reference pharmaceutical sample having the essentially same dielectric properties as the target pharmaceutical sample and about a thickness of the reference pharmaceutical sample into a solid fraction of the target pharmaceutical sample , wherein the information about the composition of the reference pharmaceutical sample comprises pairs of permittivity of the reference pharmaceutical sample and a corresponding solid fraction ratio of the reference pharmaceutical sample. positioning the target pharmaceutical sample in the operation space of the solid fraction sensor , determining a capacitance between the first and second conductor elements with the target pharmaceutical sample located in the operation space , and converting the determined capacitance together with information about a composition of a reference pharmaceutical sample having the essentially same dielectric properties as the target pharmaceutical sample and about a thickness of the reference pharmaceutical sample into a solid fraction of the target pharmaceutical sample , wherein the information about the composition of the reference pharmaceutical sample comprises pairs of permittivity of the reference pharmaceutical sample and a corresponding solid fraction ratio of the reference pharmaceutical sample.
An in vitro method for the detection of heparin-induced thrombocytopenia antibodies (HIT Abs) in a biological sample comprising i) providing a solid phase support, wherein said solid support is coated with cells or cell membranes on the surface, ii) binding of platelet factor 4 (PF4) to said cells or cell membranes on the solid phase support, iii) incubating the solid phase support of step ii) with a biological sample, iv) binding of HIT Abs which are present in said biological sample to PF4 on said cells or cell membranes on the solid phase support, v) adhering a secondary anti-human antibody, which is preferably labeled and is capable of binding to the bound HIT Abs on said cells on the solid phase support, and vi) detecting the presence of the secondary anti-human antibody, wherein the detection of said secondary anti-human antibody is a positive indicator for the presence of HIT Abs in the biological sample, characterized in that said cells or cell membranes on the solid phase support, are cancer cells or membranes from cancer cells. i) providing a solid phase support, wherein said solid support is coated with cells or cell membranes on the surface, ii) binding of platelet factor 4 (PF4) to said cells or cell membranes on the solid phase support, iii) incubating the solid phase support of step ii) with a biological sample, iv) binding of HIT Abs which are present in said biological sample to PF4 on said cells or cell membranes on the solid phase support, v) adhering a secondary anti-human antibody, which is preferably labeled and is capable of binding to the bound HIT Abs on said cells on the solid phase support, and vi) detecting the presence of the secondary anti-human antibody,
A computer-implemented method of automatically identifying a reference vessel in an ultrasound image, the method comprising: segmenting (S3) the image to identify an organ; locating (S4) a predetermined anatomical landmark specific to the organ; identifying (S5) vasculature within and/or in the vicinity of the organ; and selecting (S6) a reference vessel from the vasculature that has a size within a predetermined size range and a location with a predetermined distance range from the predetermined anatomical landmark. segmenting (S3) the image to identify an organ; locating (S4) a predetermined anatomical landmark specific to the organ; identifying (S5) vasculature within and/or in the vicinity of the organ; and selecting (S6) a reference vessel from the vasculature that has a size within a predetermined size range and a location with a predetermined distance range from the predetermined anatomical landmark.
A thermal weeder diffuser for a thermal weeder which is capable of producing a jet of hot air along an axis , the thermal weeder diffuser comprising: at least one deflector arranged across the hot air jet axis, so as to deflect hot air radially; and a shield comprising a first opening adapted to allow ingress of air from the weeder to the inside of the shield and a second opening adapted to allow application of said air to an area to be treated; wherein the deflector is carried on the shield such that if the shield is removed from the weeder the deflector is also removed from the weeder , the shield surrounds the deflector , and the deflector has at least one aperture for allowing air from a weeder outlet to pass therethrough to ensure even temperature distribution in central regions shielded by the deflector, characterised in that the shield further comprises at least one exit opening defined in a wall of the shield for allowing exit of air from the interior of the shield after application to the area to be treated, wherein the at least one exit opening is provided towards an end of the shield which is furthest from the axis of the air jet. at least one deflector arranged across the hot air jet axis, so as to deflect hot air radially; and a shield comprising a first opening adapted to allow ingress of air from the weeder to the inside of the shield and a second opening adapted to allow application of said air to an area to be treated; wherein the deflector is carried on the shield such that if the shield is removed from the weeder the deflector is also removed from the weeder , the shield surrounds the deflector , and the deflector has at least one aperture for allowing air from a weeder outlet to pass therethrough to ensure even temperature distribution in central regions shielded by the deflector, characterised in that the shield further comprises at least one exit opening defined in a wall of the shield for allowing exit of air from the interior of the shield after application to the area to be treated, wherein the at least one exit opening is provided towards an end of the shield which is furthest from the axis of the air jet.
A compound of the general Formula (I) and/or a pharmaceutically acceptable salt thereof, wherein R is halogen, -CF 3 , -OCF 3 , -OCH 3 , -CH 3 or CN; and A is a pyridinyl or oxazolyl group substituted with at least one substituent selected from halo-(C 1-6 -alkyl), halo-(C 1-3 -alkyl)oxy(C 2-4 -alkyl), or halo-(C 1-3 -alkyl)oxy(C 2-4 -alkyl)oxy(C 2-4 -alkyl). R is halogen, -CF 3 , -OCF 3 , -OCH 3 , -CH 3 or CN; and A is a pyridinyl or oxazolyl group substituted with at least one substituent selected from halo-(C 1-6 -alkyl), halo-(C 1-3 -alkyl)oxy(C 2-4 -alkyl), or halo-(C 1-3 -alkyl)oxy(C 2-4 -alkyl)oxy(C 2-4 -alkyl).
A snow removal trailer comprising at least one axle and provided with a drawbar for hitching to a towing vehicle , a snow plough being mounted on at least one of the sides of the trailer , said plough being movable between an inoperative position wherein a main longitudinal axis (A12) of the plough is oriented parallel to a direction (D) of travel of the trailer and an operative position wherein the main longitudinal axis (A12) of the plough is oriented at an angle with respect to the direction (D) of travel of the trailer , characterised in that the plough includes a rectangular main body with at least one end , also rectangular, of the plough arranged at an angle with respect to a main longitudinal axis (A12) of the main body of the plough and in that a main longitudinal axis (A13) of said end forms, with the main longitudinal axis (A12) of the main body of the plough , an angle (α1) of between 25° and 35°.